Clearmind Medicine (CMND) Retained Earnings (2021 - 2026)
Clearmind Medicine (CMND) posted quarterly Retained Earnings of -$33.8 million for Q2 2026, down 30.54% year-over-year from -$48.6 million in Q2 2025, and down 6.45% quarter-over-quarter from -$31.7 million in Q1 2026.
Clearmind Medicine (CMND) Retained Earnings (2021 - 2026) Analysis & Trends
Clearmind Medicine's Retained Earnings history runs 6 years deep, the most recent figure standing at -$33.8 million for Q2 2026.
- In Q2 2026, Retained Earnings fell 30.54% year-over-year to -$33.8 million; the TTM figure through Apr 2026 stood at -$33.8 million (down 30.54% YoY), while the FY2025 annual figure was -$27.9 million, down 16.06% from the prior year.
- Retained Earnings for Q2 2026 stood at -$33.8 million, down from -$31.7 million in the prior quarter.
- The five-year high for Retained Earnings was -$10.4 million in Q4 2022, with the low at -$33.8 million in Q2 2026.
- The 5-year median for Retained Earnings is -$23.1 million (2024), against an average of -$22.0 million.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings tumbled 195.31% in 2022, then retreated 16.06% in 2025.
- Clearmind Medicine's Retained Earnings stood at -$10.4 million in 2022, then tumbled by 79.99% to -$18.8 million in 2023, then retreated by 28.0% to -$24.0 million in 2024, then fell by 16.06% to -$27.9 million in 2025, then retreated by 21.17% to -$33.8 million in 2026.
- Business Quant data shows CMND's Retained Earnings at -$33.8 million in Q2 2026, -$31.7 million in Q1 2026, and -$27.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - | -33.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -33.78 Mn |
| Jan 31, 2026 | -31.73 Mn |
| Oct 31, 2025 | -27.88 Mn |
| Jul 31, 2025 | -27.19 Mn |
| Apr 30, 2025 | -25.88 Mn |
| Jan 31, 2025 | -25.09 Mn |
| Oct 31, 2024 | -24.02 Mn |
| Jul 31, 2024 | -23.14 Mn |
| Apr 30, 2024 | -21.04 Mn |
| Jan 31, 2024 | -20.14 Mn |
| Oct 31, 2023 | -18.77 Mn |
| Jul 31, 2023 | -14.70 Mn |
| Apr 30, 2023 | -14.12 Mn |
| Jan 31, 2023 | -12.09 Mn |
| Oct 31, 2022 | -10.43 Mn |
| Oct 31, 2021 | -3.53 Mn |